Estrella Immunopharma, Inc. ESLA
0.48
0.01
2.13%
as of 25 Sep
- Market cap
- $20.5M
- P/E
- 0.0×
Follow ESLA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
0.20 | 0.24 | 0.12 | 0.15 |
+8 more quarters Free account |
Net Debt/EBITDA |
0.07 | 0.84 | 2.26 | 0.34 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.77 | 2.92 | 0.29 | 0.15 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.04) | (0.16) | 0.00 | (0.02) | |
Cash per Share |
0.00 | 0.05 | 0.04 | 0.04 | |
Shareholders Equity per Share |
(0.17) | (0.13) | (0.28) | (0.27) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.17) | (0.13) | (0.28) | (0.27) | |
Free Cash Flow |
(1.78) | (6.70) | (0.18) | (0.73) | |
Working Capital |
(7.43) | (6.77) | (11.87) | (11.34) | |
Net Current Asset Value |
(7.43) | (6.77) | (11.87) | (11.34) | |
| Other line items | |||||
Quick Ratio |
0.02 | 0.22 | 0.10 | 0.12 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.04) | (0.16) | 0.00 | (0.02) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
0.01 | 0.01 | 0.28 | 0.01 | |
Average Assets |
2.40 | 3.05 | 3.16 | 3.63 | |
Average Common Equity |
(6.76) | (3.55) | (5.11) | (4.55) | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates